Hims & Hers Health (NYSE:HIMS) Cut to Neutral at BTIG Research

BTIG Research cut shares of Hims & Hers Health (NYSE:HIMS) from a buy rating to a neutral rating in a research note issued to investors on Tuesday morning, Marketbeat.com reports.

A number of other research firms also recently issued reports on HIMS. Citigroup lowered their price target on Hims & Hers Health from $30.00 to $16.50 and set a “sell” rating for the company in a research report on Monday, February 9th. Deutsche Bank Aktiengesellschaft set a $31.00 target price on Hims & Hers Health and gave the stock a “hold” rating in a report on Tuesday, February 10th. Wall Street Zen downgraded shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Evercore assumed coverage on shares of Hims & Hers Health in a research report on Monday, January 12th. They set an “in-line” rating and a $33.00 price target on the stock. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Hims & Hers Health in a research report on Monday, December 29th. Two research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and four have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Hims & Hers Health presently has an average rating of “Reduce” and an average target price of $32.27.

Hims & Hers Health Stock Performance

Shares of HIMS stock opened at $15.61 on Tuesday. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.64 and a current ratio of 1.90. The firm has a market capitalization of $3.55 billion, a price-to-earnings ratio of 30.61, a price-to-earnings-growth ratio of 3.38 and a beta of 2.43. Hims & Hers Health has a one year low of $13.74 and a one year high of $70.43. The company has a 50 day moving average price of $27.02 and a 200 day moving average price of $39.43.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.06. The company had revenue of $617.82 million for the quarter, compared to analyst estimates of $619.48 million. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. Hims & Hers Health’s revenue for the quarter was up 28.4% on a year-over-year basis. During the same quarter last year, the business earned $0.11 EPS. Sell-side analysts anticipate that Hims & Hers Health will post 0.29 EPS for the current year.

Hims & Hers Health declared that its board has approved a stock repurchase program on Monday, November 17th that authorizes the company to buyback $250.00 million in outstanding shares. This buyback authorization authorizes the company to purchase up to 3% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board believes its stock is undervalued.

Insider Transactions at Hims & Hers Health

In other news, insider Irene Becklund sold 8,411 shares of the company’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $308,767.81. Following the completion of the transaction, the insider directly owned 2,126 shares in the company, valued at approximately $78,045.46. This represents a 79.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Deborah M. Autor sold 7,054 shares of the firm’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $258,952.34. Following the sale, the insider directly owned 6,175 shares of the company’s stock, valued at approximately $226,684.25. The trade was a 53.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 82,963 shares of company stock worth $2,944,621 over the last 90 days. 13.71% of the stock is owned by corporate insiders.

Institutional Trading of Hims & Hers Health

Several institutional investors have recently added to or reduced their stakes in the stock. Pathway Capital Management LP acquired a new stake in Hims & Hers Health during the third quarter valued at approximately $6,766,000. Ethic Inc. acquired a new position in shares of Hims & Hers Health in the 2nd quarter worth approximately $348,000. Steadview Capital Management LLC increased its holdings in shares of Hims & Hers Health by 80.0% in the 3rd quarter. Steadview Capital Management LLC now owns 701,845 shares of the company’s stock valued at $39,809,000 after acquiring an additional 311,845 shares during the last quarter. State of Michigan Retirement System raised its position in shares of Hims & Hers Health by 49.2% during the 3rd quarter. State of Michigan Retirement System now owns 2,057,700 shares of the company’s stock valued at $116,713,000 after acquiring an additional 678,600 shares in the last quarter. Finally, Carnegie Investment Counsel boosted its holdings in Hims & Hers Health by 25.4% in the third quarter. Carnegie Investment Counsel now owns 303,909 shares of the company’s stock worth $17,238,000 after purchasing an additional 61,560 shares during the period. 63.52% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Management continues to emphasize growth and is pursuing a large international expansion via a planned acquisition of Eucalyptus, which could boost scale and addressable market outside the U.S. Hims And Hers Balances GLP 1 Scrutiny With Eucalyptus Expansion Plans
• Neutral Sentiment: Investor interest is elevated — unusually large options volume was reported, signaling higher speculative or hedging activity that can amplify moves in either direction. Hims & Hers Health Sees Unusually Large Options Volume (NYSE:HIMS)
• Neutral Sentiment: Comparative coverage (HIMS vs. AMWL) highlights differing telehealth strategies; useful for investors evaluating sector exposure but not an immediate catalyst. HIMS vs. AMWL: Which Telehealth Stock Is the Better Investment Now?
• Negative Sentiment: The SEC has opened an inquiry into Hims’ disclosures about compounded GLP‑1 (semaglutide) products, increasing regulatory risk and disclosure uncertainty. Hims & Hers Stock Faces Heavy Sell-Off Amid SEC Probe Into GLP-1 Disclosures
• Negative Sentiment: Novo Nordisk filed suit alleging patent infringement over compounded weight‑loss drugs; Hims withdrew its compounded semaglutide product—potential legal and liability exposure. Hims And Hers Balances GLP 1 Scrutiny With Eucalyptus Expansion Plans
• Negative Sentiment: The Law Offices of Frank R. Cruz announced an investor investigation into whether the board breached fiduciary duties related to these matters, which raises litigation risk and governance scrutiny. The Law Offices of Frank R. Cruz Announces Investigation of Hims & Hers Health, Inc. (HIMS) on Behalf of Investors
• Negative Sentiment: Multiple analyst actions: Citigroup cut its price target to $13.25 and BTIG downgraded HIMS to Neutral; those notes prompted downgrades and contributed to heavy intraday selling. Citigroup Lowers Hims & Hers Health (NYSE:HIMS) Price Target to $13.25 BTIG Research Downgrades Hims & Hers Health (NYSE:HIMS) to Neutral
• Negative Sentiment: Shares have hit new lows after the analyst activity and headlines; commentary also flagged potential near‑term pressure from a Super Bowl ad and changes to shipping cadence that could affect short‑term volumes. Hims & Hers Stock Stumbles – Cautions About Pressure Due To Super Bowl Ad, Change In Shipping Cadences
• Negative Sentiment: Overall coverage (TipRanks, Market commentary) highlights elevated reputation, partnership and liability risks from compounded‑drug scrutiny—factors that could weigh on sentiment until legal/regulatory clarity is reached. Regulatory Scrutiny of Compounded Drugs Puts Hims & Hers’ Growth, Partnerships, and Liability Risk in the Spotlight

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.